Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Therapy With Manufactured Autologous T-Cells Expressing a Second Generation Chimeric Antigen Receptor (CAR) for Treatment of T-Cell Malignancies Expressing CD5 Antigen

NCT03081910 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT03081910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03081910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Therapy With Manufactured Autologous T-Cells Expressing a Second Generation Chimeric Antigen Receptor (CAR) for Treatment of T-Cell Malignancies Expressing CD5 Antigen
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Recruiting
Start date
November 1, 2017
Completion date
September 1, 2040
Enrollment
54 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

t-cell acute lymphoblastic leukemia, t-cell acute lymphoblastic lymphoma, t-non-hodgkin lymphoma